第4期非小細胞肺癌患者におけるEIK1001とペムブロリズマブおよび化学療法の併用に関する安全性と有効性の研究 (TeLuRide-008)
EIK1001をペムブロリズマブおよび化学療法と併用した、ステージ4非小細胞肺癌患者を対象とした国際共同第2/3相二重盲検プラセボ対照ランダム化比較試験(TeLuRide-008)。
This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.
調査の概要
状態
詳細な説明
This is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered IV in combination with pembrolizumab and histologically appropriate chemotherapy (pemetrexed plus either carboplatin or cisplatin) to participants with Stage 4 non-squamous or (carboplatin plus either paclitaxel or nab-paclitaxel) for participants with squamous NSCLC who have not received prior systemic therapy. The study is conducted in 2 phases (Phase 2 and Phase 3) and analyzed in 3 parts (dose optimization, dose expansion and confirmatory hypothesis testing).
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Elelta Shiferraw
- 電話番号:314-209-3659
- メール:shiferrawe@eikontx.com
研究場所
-
-
Alabama
-
Daphne、Alabama、アメリカ、36526
- 募集
- Southern Cancer Center, P.C.
-
-
California
-
Glendale、California、アメリカ、91204
- 募集
- Los Angeles Cancer Network
-
Orange、California、アメリカ、92868
- 募集
- Providence St. Joseph Hospital
-
-
Colorado
-
Pueblo、Colorado、アメリカ、81103
- 募集
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Doral、Florida、アメリカ、33172
- 募集
- Omnicure Clinical Research
-
Plantation、Florida、アメリカ、33322
- 募集
- Florida Clinical Trials Group
-
Tamarac、Florida、アメリカ、33321
- 募集
- Florida Clinical Trials Group - Tamarac
-
-
Illinois
-
Peoria、Illinois、アメリカ、61637
- 募集
- OSF Saint Francis Medical Center
-
-
New Mexico
-
Albuquerque、New Mexico、アメリカ、87102
- 募集
- University of New Mexico - Comprehensive Cancer Center
-
-
New York
-
Mineola、New York、アメリカ、11501
- 募集
- NYU Langone Hospital Long Island
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone Hospital Manhattan
-
The Bronx、New York、アメリカ、10461
- 募集
- Jacobi Medical Center - Albert Einstein College of Medicine
-
White Plains、New York、アメリカ、10601
- 募集
- White Plains Hospital
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tennessee Oncology
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- 募集
- The Center for Cancer and Blood Disorders
-
-
Virginia
-
Blacksburg、Virginia、アメリカ、24060
- 募集
- Blue Ridge Cancer Center
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists, PC
-
Winchester、Virginia、アメリカ、22601
- 募集
- Shenandoah Oncology P.C.
-
-
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、2000
- 募集
- Fundación de Estudios Clínicos
-
-
-
-
-
Roma、イタリア、00128
- 募集
- Policlinico Campus Bio-Medico
-
-
-
-
New South Wales
-
Frenchs Forest、New South Wales、オーストラリア、2086
- 募集
- Cancer Care Northern Beaches
-
Waratah、New South Wales、オーストラリア、2298
- 募集
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Frankston、Victoria、オーストラリア、3199
- 募集
- Peninsula and Southeast Oncology (PASO) Medical
-
Saint Albans、Victoria、オーストラリア、3021
- 募集
- Sunshine Hospital - Western Health
-
-
-
-
-
Linz、オーストリア、4020
- 募集
- Kepler Universitaetsklinikum
-
-
-
-
-
Athens、ギリシャ、11516
- 募集
- Henry Dunant Hospital Center
-
Thessaloniki、ギリシャ、55535
- 募集
- 4th Department of Medical Oncology, European Interbalkan Medical Center
-
-
Central Macedonia
-
Thessaloniki、Central Macedonia、ギリシャ、55535
- 募集
- Hospital Genesis
-
-
-
-
-
Barcelona、スペイン、08028
- 募集
- Instituto Oncologico Dr. Rosell (IOR)
-
Girona、スペイン、17007
- 募集
- Institut Catala D'Oncologia de Girona
-
Málaga、スペイン、29004
- 募集
- Hospital Quirónsalud Málaga
-
-
Cadiz
-
Jerez de la Frontera、Cadiz、スペイン、11407
- 募集
- Hospital Universitario de Jerez de la Frontera
-
-
Castellón
-
Castellon、Castellón、スペイン、12006
- 募集
- Consorci Hospitalari Provincial de Castello
-
-
Malaga
-
Málaga、Malaga、スペイン、29011
- 募集
- Hospital Regional Universitario de Malaga
-
-
-
-
-
Hamburg、ドイツ、22087
- 募集
- Katholische Marienkrankenhaus gGmbH
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- 募集
- University Hospital Carl Gustav Carus Dresden
-
-
-
-
-
Brasília、ブラジル、71635-580
- 募集
- Hospital Brasília Unidade Lago Sul
-
-
Ceará
-
Fortaleza、Ceará、ブラジル、60336-232
- 募集
- CRIO - Centro Regional Integrado de Oncologia
-
-
Espírito Santo
-
Cachoeiro de Itapemirim、Espírito Santo、ブラジル、29308-065
- 募集
- Hospital Evangélico de Cachoeiro de Itapemirim
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、40170-110
- 募集
- Nucleo de Oncologia da Bahia
-
-
Rio Grande do Sul
-
Santa Maria、Rio Grande do Sul、ブラジル、97015-450
- 募集
- Clinica de Hematologia e Oncologia Viver Ltda
-
-
Rio de Janeiro
-
Rio de Janeiro、Rio de Janeiro、ブラジル、22250-905
- 募集
- Oncoclinicas Rio de Janeiro
-
-
-
-
-
Brussels、ベルギー、1020
- 募集
- Centre Hospitalier Universitaire Brugmann
-
-
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-864
- 募集
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
-
-
-
Cluj
-
Cluj-Napoca、Cluj、ルーマニア、400641
- 募集
- Medisprof Cancer Center
-
-
-
-
Gauteng
-
Saxonwold、Gauteng、南アフリカ、2196
- 募集
- The Medical Oncology Centre of Rosebank
-
-
Western Cape
-
George、Western Cape、南アフリカ、6529
- 募集
- Task Eden
-
-
-
-
-
Seoul、韓国、03181
- 募集
- Kangbuk Samsung Medical Center (KBSMC)
-
-
Daegu
-
Daegu、Daegu、韓国、42415
- 募集
- Yeungnam University College of Medicine
-
-
Guro-gu
-
Seoul、Guro-gu、韓国、08308
- 募集
- Korea University Medical Center-Korea University Guro Hospital - Women's Cancer Center
-
-
Incheon Gwang'Yeogsi
-
Incheon、Incheon Gwang'Yeogsi、韓国、21565
- 募集
- Gachon University - Gil Medical Center
-
-
Jeollanam-do
-
Hwasun、Jeollanam-do、韓国、58128
- 募集
- Chonnam National University Hwasun Hospital (CNUHH)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
-
Participant must be ≥ 18 years old at the time of signing the informed consent.
-
Participant has a life expectancy of at least 3 months.
-
Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC.
-
Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country.
-
Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.
-
Participant has not received prior systemic therapy for advanced/metastatic NSCLC.
Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.
-
Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.
-
Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is < 3yrs old).
Key Exclusion Criteria:
- has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC.
- is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo.
- has had major surgery (< 3 weeks prior to the first dose of study intervention administration).
- has received a live-virus vaccination within 30 days of the start of study intervention initiation.
- has received radiation therapy within 7 days of the first dose of study intervention administration.
- has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Arm 1 (Placebo in Combination with SOC)
Participants in this arm will receive EIK1001 Placebo + Standard of Care (SOC). |
Placebo control PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC |
|
実験的:Arm 2 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 1) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
|
実験的:Arm 3 (EIK1001 in Combination with SOC)
Participants in this arm will receive EIK1001 (Selected Dose 2) + Standard of Care (SOC). |
PD-1 inhibitor SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for squamous NSCLC SOC Chemotherapy for non-squamous NSCLC EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:Through study completion, up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by BICR, or death due to any cause, whichever occurs first |
Through study completion, up to 6 years
|
|
Overall survival (OS)
時間枠:Through study completion, up to 10 years
|
OS defined as the time from the first dose of study medication to death due to any cause |
Through study completion, up to 10 years
|
|
Objective Response (OR)
時間枠:Through study completion, up to 6 years
|
Objective response (OR) is defined as participants who demonstrate complete response (CR) or partial response (PR) by RECIST 1.1 as assessed by the Investigator, adverse events (AEs), and discontinuation of study intervention due to an AE (Dose Optimization Only). |
Through study completion, up to 6 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response (OR)
時間枠:Up to 6 years
|
Objective response (OR) is defined as participants who have a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 by BICR |
Up to 6 years
|
|
Duration of response (DOR)
時間枠:Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by BICR. |
Up to 6 years
|
|
Progression-free survival (PFS) by Investigator
時間枠:Up to 6 years
|
Progression-free survival (PFS) is defined as the time from the first dose of the study medication to the first documented disease progression according to RECIST 1.1 by Investigator, or death due to any cause, whichever occurs first. |
Up to 6 years
|
|
Overall Response Rate (ORR) by Investigator
時間枠:Up to 6 years
|
Objective Response as defined by participants who demonstrate confirmed CR or PR according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Duration of Response (DOR) by Investigator
時間枠:Up to 6 years
|
DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, according to RECIST 1.1 by Investigator. |
Up to 6 years
|
|
Incidence of Adverse Events (AEs)
時間枠:Up to 2.5 years
|
Adverse Events (AEs) and discontinuation of study treatment due to any AE. |
Up to 2.5 years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Nishitha Reddy、Eikon Therapeutics
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- EIK1001-008
- 2025-525013-23-00 (Ctis)
- KEYNOTE-G57 (その他の識別子:Merck Sharp & Dohme LLC)
- MK-3475-G57 (その他の識別子:Merck Sharp & Dohme LLC)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。